T. Rowe Price Associates
VMD icon

T. Rowe Price Associates’s Viemed Healthcare VMD Stock Holding History

T. Rowe Price Associates’s Portfolio VMD Stock Details VMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Buy
27,976
+3,547
+15% +$35.1K ﹤0.01% 2830
2026
Q1 		$225K Buy
24,429
+5,865
+32% +$48.8K ﹤0.01% 2802
2025
Q4 		$138K Hold
18,564
– – ﹤0.01% 2898
2025
Q3 		$127K Buy
18,564
+1,663
+10% +$11.3K ﹤0.01% 2885
2025
Q2 		$117K Buy
16,901
+2,141
+15% +$14.5K ﹤0.01% 2863
2025
Q1 		$108K Buy
14,760
+1,755
+13% +$13.8K ﹤0.01% 2807
2024
Q4 		$105K Buy
13,005
+1,997
+18% +$17.3K ﹤0.01% 2825
2024
Q3 		$81K Buy
11,008
+286
+3% +$2.04K ﹤0.01% 2861
2024
Q2 		$71K Buy
10,722
+512
+5% +$3.86K ﹤0.01% 2803
2024
Q1 		$97K Buy
+10,210
New +$87.5K ﹤0.01% 2790

Other funds holding VMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Forager Capital Management Birmingham, Alabama $266M AUM 40% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

T. Rowe Price Associates's VMD Position: Q2 2026 in Review

T. Rowe Price Associates increased its Viemed Healthcare (VMD) stake by 15% in Q2 2026, buying an estimated $35.1K and bringing the position to 27,976 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #2830.

T. Rowe Price Associates first reported a position in VMD in Q1 2024 and has held it in 10 quarters since. 166 funds tracked by Wall St. Rank hold VMD as of Q2 2026.

  • T. Rowe Price Associates held 27,976 shares of Viemed Healthcare worth $319K as of Q2 2026.
  • T. Rowe Price Associates bought 3,547 Viemed Healthcare shares in Q2 2026, an estimated $35.1K.
  • Viemed Healthcare made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2830 holding.
  • T. Rowe Price Associates first reported a position in Viemed Healthcare in Q1 2024 and has held it in 10 quarters since.
  • 166 funds tracked by Wall St. Rank held Viemed Healthcare as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.